Combo-vs-Mono Decision Aid for First-Line EGFR-Mutated NSCLC
A tablet tool showing lung cancer patients the trade-off between a stronger drug combo and more severe side effects.
A visit-time tablet tool that shows newly diagnosed EGFR-mutated lung cancer patients and their doctors the quantified choice between osimertinib alone or with chemotherapy: about 10 extra months of median survival versus severe side-effect risk doubling from 34% to 70%.
Concept
A point-of-care shared decision-making tool (tablet/web) used at the first-line treatment visit for patients with newly diagnosed EGFR-mutated (exon 19 deletion or L858R) advanced NSCLC. The clinician enters age, performance status, and relevant comorbidities (neuropathy, hearing, renal function); the patient completes a two-minute preference exercise weighing survival length against avoiding severe side effects and time in infusion chairs. The tool renders a side-by-side, plain-language comparison of osimertinib monotherapy versus osimertinib plus platinum-pemetrexed: median overall survival (37.6 vs 47.5 months), risk of grade 3 or higher adverse events (34% vs 70%), pill-only versus infusion schedule, and osimertinib discontinuation risk (7% vs 12%). A one-page summary is saved to the EHR, documenting an informed, preference-sensitive regimen choice.
Why now
The FLAURA2 final overall survival analysis (557 randomized patients) turns this from a theoretical into a quantifiable trade-off for the first time: adding platinum-pemetrexed chemotherapy to first-line osimertinib extended median overall survival from 37.6 to 47.5 months (hazard ratio for death 0.77; 95% CI 0.61-0.96; P=0.02), but grade 3 or higher adverse events of any cause rose from 34% to 70%. As guidelines incorporate the combination, community practices — where most of these patients are treated — need a standardized, evidence-anchored way to present both numbers and elicit patient priorities, rather than defaulting to monotherapy or reflexively adding chemotherapy.
Written by GLM · 12 Oct 2026
AI assessment
A highly focused, evidence-backed decision aid that converts a specific clinical trial trade-off into a practical point-of-care tool for oncology clinics.
- Evidence strength 5/5
- The idea is directly derived from the FLAURA2 final OS analysis, using the exact median survival and adverse event percentages reported in the phase 3 trial.
- Market pull 4/5
- Oncologists in community practices face significant pressure to standardize care and document informed consent for aggressive regimens, creating a clear pull for decision-support tools.
- Novelty & moat 4/5
- While similar to the ASCVD Incretin Switch Card, this applies a specific, high-stakes oncology trade-off to a distinct patient population with a unique risk-benefit profile.
- Feasibility 5/5
- The tool is a straightforward digital interface for data entry and visualization, requiring no complex algorithms or new biological assays to build a prototype.
- Wedge clarity 5/5
- The wedge is extremely sharp: a single, specific decision point (Mono vs. Combo) for a specific mutation (EGFR) in a specific cancer (NSCLC).
- Simplicity / focus 5/5
- The product avoids 'platform' creep, focusing exclusively on one clinical decision and its documentation in the EHR.
Scored by Gemma 4 · 12 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- The US Oncology Networkcompany
The largest US community-oncology network treats a substantial share of first-line EGFR-mutated NSCLC patients; a standardized, evidence-anchored decision aid reduces unwarranted variation between defaulting to monotherapy and reflexively adding chemotherapy.
- LUNGevity Foundationorganization
The leading lung-cancer patient advocacy organization runs EGFR-specific education programs and distributes tools that help newly diagnosed patients make informed treatment choices — a validated trade-off aid fits directly into that mission.
- GO2 for Lung Cancerorganization
Patient-advocacy organization focused on lung cancer treatment education and survivorship; a shared decision-making tool for this newly preference-sensitive choice is a concrete resource for its patient community.
- Dana-Farber Cancer Instituteorganization
Academic cancer center with a large thoracic oncology service and shared decision-making programs; it could pilot the aid, lend credibility, and standardize the regimen conversation across its network.
Research it builds on
- Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLCPasi Antero Janne, David Planchard, Kunihiko Kobayashi et al. · 2025 · 114 citationsAll ideas from this paper →